Compare BlackBerry Limited (BB) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackBerry Limited vs Boston Scientific Corporation — how do they compare? BlackBerry Limited trades at $11.1 (market cap $6.26B), while Boston Scientific Corporation trades at $42.65 (market cap $66.37B). The key difference: Boston Scientific Corporation is far larger — about 10.6× BlackBerry Limited's market cap, and BlackBerry Limited is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BB | BSX | |
|---|---|---|
Market Cap | $6.26B | $66.37B |
Sector | Technology | Health |
52-Week High | $12.81 | $108.14 |
52-Week Low | $3.15 | $42.63 |
Enterprise Value | $6.13B | $75.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $10.71, down 2.37% today, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q1 2026 earnings beat expectations with EPS of $0.06 versus $0.05 expected, driven by QNX software growth. Revenue for 2025 was $534.90M with a net loss of $79M, but 2026 projects a return to profitability. Positive news highlights QNX expansion into robotics and industrial automation.
Outlook is cautiously optimistic as the company's turnaround gains traction, but high valuation ratios (P/E 107.1) and mixed analyst sentiment (14% buy, 86% hold) suggest execution risks remain. Key opportunities include QNX's market penetration, while risks involve competitive pressures and achieving sustained profitability.
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
